Cargando…
Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817557/ https://www.ncbi.nlm.nih.gov/pubmed/32829460 http://dx.doi.org/10.1007/s00277-020-04227-8 |
| _version_ | 1783638664933277696 |
|---|---|
| author | Wullenkord, Ramona Reicherts, Christian Mikesch, Jan-Henrik Marx, Julia Wethmar, Klaus Albring, Jörn Call, Simon Lenz, Georg Stelljes, Matthias |
| author_facet | Wullenkord, Ramona Reicherts, Christian Mikesch, Jan-Henrik Marx, Julia Wethmar, Klaus Albring, Jörn Call, Simon Lenz, Georg Stelljes, Matthias |
| author_sort | Wullenkord, Ramona |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7817557 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78175572021-01-25 Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia Wullenkord, Ramona Reicherts, Christian Mikesch, Jan-Henrik Marx, Julia Wethmar, Klaus Albring, Jörn Call, Simon Lenz, Georg Stelljes, Matthias Ann Hematol Letter to the Editor Springer Berlin Heidelberg 2020-08-22 2021 /pmc/articles/PMC7817557/ /pubmed/32829460 http://dx.doi.org/10.1007/s00277-020-04227-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Wullenkord, Ramona Reicherts, Christian Mikesch, Jan-Henrik Marx, Julia Wethmar, Klaus Albring, Jörn Call, Simon Lenz, Georg Stelljes, Matthias Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia |
| title | Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia |
| title_full | Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia |
| title_fullStr | Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia |
| title_full_unstemmed | Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia |
| title_short | Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia |
| title_sort | sequential therapy with inotuzumab ozogamicin, cd19 car t cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817557/ https://www.ncbi.nlm.nih.gov/pubmed/32829460 http://dx.doi.org/10.1007/s00277-020-04227-8 |
| work_keys_str_mv | AT wullenkordramona sequentialtherapywithinotuzumabozogamicincd19cartcellsandblinatumomabinanelderlypatientwithrelapsedacutelymphoblasticleukemia AT reichertschristian sequentialtherapywithinotuzumabozogamicincd19cartcellsandblinatumomabinanelderlypatientwithrelapsedacutelymphoblasticleukemia AT mikeschjanhenrik sequentialtherapywithinotuzumabozogamicincd19cartcellsandblinatumomabinanelderlypatientwithrelapsedacutelymphoblasticleukemia AT marxjulia sequentialtherapywithinotuzumabozogamicincd19cartcellsandblinatumomabinanelderlypatientwithrelapsedacutelymphoblasticleukemia AT wethmarklaus sequentialtherapywithinotuzumabozogamicincd19cartcellsandblinatumomabinanelderlypatientwithrelapsedacutelymphoblasticleukemia AT albringjorn sequentialtherapywithinotuzumabozogamicincd19cartcellsandblinatumomabinanelderlypatientwithrelapsedacutelymphoblasticleukemia AT callsimon sequentialtherapywithinotuzumabozogamicincd19cartcellsandblinatumomabinanelderlypatientwithrelapsedacutelymphoblasticleukemia AT lenzgeorg sequentialtherapywithinotuzumabozogamicincd19cartcellsandblinatumomabinanelderlypatientwithrelapsedacutelymphoblasticleukemia AT stelljesmatthias sequentialtherapywithinotuzumabozogamicincd19cartcellsandblinatumomabinanelderlypatientwithrelapsedacutelymphoblasticleukemia |